Personalis, Inc. (PSNL) Social Stream



Personalis, Inc. (PSNL): $4.73

0.21 (-4.25%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add PSNL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#142 of 329

in industry

Featured Post From StockTwits About PSNL

$PSNL, John West has setup the company well for next year, with China operations, continued biopharma penetration, and a new platform for cancer diagnostics (walking into $GH territory). This one is a good LT hold and also always a top M&A candidate for $ILMN

"Mgmt. kept their FY21 revenue forecast at $85mn but shifted the expected revenue mix to reflect the strength in biopharma activity. During the call, Mgmt. noted that the Oncology segment’s new-bookto-bill ratio continued to exceed 1x in 2Q. The segment will further benefit from the initiation of commercial lab operations in Shanghai, China, in 2H21 with revenues expected in 2022. Additionally, the company secured a multimillion dollar order in 3Q for its exome-scale NeXT Liquid Biopsy, and NeXT Personal is on schedule to launch later in
2021."
Jasooon, published August 5, 2021

What Else are PSNL Traders Talking About?


Other tickers frequently mentioned alongside PSNL are GH and ILMN.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!